Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

9 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
9(75.0%)
Phase 2
2(16.7%)
Phase 1
1(8.3%)
12Total
Phase 3(9)
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07102511Phase 3Not Yet Recruiting

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

Role: lead

NCT05004675Phase 3Completed

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

Role: lead

NCT04798430Phase 3Enrolling By Invitation

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Role: lead

NCT04797104Phase 3Completed

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

Role: lead

NCT04806893Phase 3Unknown

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Role: lead

NCT04797247Phase 3Unknown

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

Role: lead

NCT04790513Phase 3Completed

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Role: lead

NCT04034485Phase 3Completed

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Role: lead

NCT05234775Phase 3Completed

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

Role: lead

NCT03847974Phase 2Completed

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Role: lead

NCT03549260Phase 2Completed

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

Role: lead

NCT03545438Phase 1Completed

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

Role: lead

All 12 trials loaded